Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
Tag: Neoadjuvant ipilimumab plus nivolumab
